A Study of Oral Oteseconazole (VT-1161) for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)
Launched by MYCOVIA PHARMACEUTICALS INC. · Jun 18, 2018
Trial Information
Current as of May 27, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Key Inclusion Criteria:
- • 3 or more episodes of acute VVC in the past 12 months
- • Positive KOH or Gram stain test
- • Total vulvovaginal signs and symptoms score of ≥3 at screening visit
- • Total vulvovaginal signs and symptoms score of \<3 at baseline visit
- • Must be able to swallow pills
- Key Exclusion Criteria:
- • Presence or a history of another vaginal or vulvar condition(s)
- • Evidence of major organ system disease
- • History of cervical cancer
- • Poorly controlled diabetes mellitus
- • Pregnant
- • Recent use of topical or systemic antifungal or antibacterial drugs
- • Recent use of immunosuppressive or systemic corticosteroid therapies
About Mycovia Pharmaceuticals Inc.
Mycovia Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing innovative therapies for patients with rare and complex diseases, particularly in the field of women’s health. Focused on addressing unmet medical needs, Mycovia leverages cutting-edge scientific research and clinical expertise to advance its product pipeline. The company's commitment to improving patient outcomes is reflected in its rigorous clinical trial programs, aimed at delivering safe and effective treatments that enhance quality of life. With a strong emphasis on collaboration and integrity, Mycovia Pharmaceuticals is poised to make significant contributions to the advancement of healthcare solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Phoenix, Arizona, United States
Little Rock, Arkansas, United States
Los Angeles, California, United States
Hartford, Connecticut, United States
Homestead, Florida, United States
North Bay Village, Florida, United States
Wichita, Kansas, United States
Hagerstown, Maryland, United States
Winston Salem, North Carolina, United States
Columbus, Ohio, United States
Columbus, Ohio, United States
Englewood, Ohio, United States
Jackson, Tennessee, United States
Frisco, Texas, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials